Non-quinolone Topoisomerase Inhibitors View Full Text


Ontology type: schema:Chapter     


Chapter Info

DATE

2018-11-11

AUTHORS

Anthony Maxwell , Natassja G. Bush , Thomas Germe , Shannon J. McKie

ABSTRACT

Fluoroquinolone antibiotics, such as ciprofloxacin, levofloxacin, and moxifloxacin, have enjoyed enormous success over the past few decades. However, resistance to these compounds is rising and causing significant concern. These drugs target the type II DNA topoisomerases, DNA gyrase, and DNA topoisomerase (topo) IV. A key feature of their success is that they cause enzyme-stabilized double-stranded breaks in DNA, which can readily lead to bacterial cell death. There are, however, many other compounds that target gyrase and topo IV both via the cleavage-complex mode of action and via other modes of inhibition, such as blocking the ATPase activity of these enzymes. The purpose of this chapter is to review our knowledge of these compounds and to discuss the possibility that one or more of these compounds will become clinically-relevant, perhaps by replacing the fluoroquinolones. Compounds covered include well-established agents, such as the aminocoumarins, which predate the quinolones in terms of their discovery, and a variety of more recently-discovered compounds whose clinical potential has yet to be fully explored. More... »

PAGES

593-618

Book

TITLE

Antimicrobial Resistance in the 21st Century

ISBN

978-3-319-78537-0
978-3-319-78538-7

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/978-3-319-78538-7_19

DOI

http://dx.doi.org/10.1007/978-3-319-78538-7_19

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1109848723


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/06", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Biological Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/0601", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Biochemistry and Cell Biology", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Department of Biological Chemistry, John Innes Centre, Norwich Research Park, NR4 7UH, Norwich, UK", 
          "id": "http://www.grid.ac/institutes/grid.14830.3e", 
          "name": [
            "Department of Biological Chemistry, John Innes Centre, Norwich Research Park, NR4 7UH, Norwich, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Maxwell", 
        "givenName": "Anthony", 
        "id": "sg:person.01274446176.29", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01274446176.29"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Biological Chemistry, John Innes Centre, Norwich Research Park, NR4 7UH, Norwich, UK", 
          "id": "http://www.grid.ac/institutes/grid.14830.3e", 
          "name": [
            "Department of Biological Chemistry, John Innes Centre, Norwich Research Park, NR4 7UH, Norwich, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Bush", 
        "givenName": "Natassja G.", 
        "id": "sg:person.0753423055.87", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0753423055.87"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Biological Chemistry, John Innes Centre, Norwich Research Park, NR4 7UH, Norwich, UK", 
          "id": "http://www.grid.ac/institutes/grid.14830.3e", 
          "name": [
            "Department of Biological Chemistry, John Innes Centre, Norwich Research Park, NR4 7UH, Norwich, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Germe", 
        "givenName": "Thomas", 
        "id": "sg:person.0630632607.32", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0630632607.32"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Biological Chemistry, John Innes Centre, Norwich Research Park, NR4 7UH, Norwich, UK", 
          "id": "http://www.grid.ac/institutes/grid.14830.3e", 
          "name": [
            "Department of Biological Chemistry, John Innes Centre, Norwich Research Park, NR4 7UH, Norwich, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "McKie", 
        "givenName": "Shannon J.", 
        "id": "sg:person.015610331447.17", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.015610331447.17"
        ], 
        "type": "Person"
      }
    ], 
    "datePublished": "2018-11-11", 
    "datePublishedReg": "2018-11-11", 
    "description": "Fluoroquinolone antibiotics, such as ciprofloxacin, levofloxacin, and moxifloxacin, have enjoyed enormous success over the past few decades. However, resistance to these compounds is rising and causing significant concern. These drugs target the type II DNA topoisomerases, DNA gyrase, and DNA topoisomerase (topo) IV. A key feature of their success is that they cause enzyme-stabilized double-stranded breaks in DNA, which can readily lead to bacterial cell death. There are, however, many other compounds that target gyrase and topo IV both via the cleavage-complex mode of action and via other modes of inhibition, such as blocking the ATPase activity of these enzymes. The purpose of this chapter is to review our knowledge of these compounds and to discuss the possibility that one or more of these compounds will become clinically-relevant, perhaps by replacing the fluoroquinolones. Compounds covered include well-established agents, such as the aminocoumarins, which predate the quinolones in terms of their discovery, and a variety of more recently-discovered compounds whose clinical potential has yet to be fully explored.", 
    "editor": [
      {
        "familyName": "Fong", 
        "givenName": "I. W.", 
        "type": "Person"
      }, 
      {
        "familyName": "Shlaes", 
        "givenName": "David", 
        "type": "Person"
      }, 
      {
        "familyName": "Drlica", 
        "givenName": "Karl", 
        "type": "Person"
      }
    ], 
    "genre": "chapter", 
    "id": "sg:pub.10.1007/978-3-319-78538-7_19", 
    "inLanguage": "en", 
    "isAccessibleForFree": false, 
    "isPartOf": {
      "isbn": [
        "978-3-319-78537-0", 
        "978-3-319-78538-7"
      ], 
      "name": "Antimicrobial Resistance in the 21st Century", 
      "type": "Book"
    }, 
    "keywords": [
      "compounds", 
      "fluoroquinolone antibiotics", 
      "type II DNA topoisomerases", 
      "double-strand breaks", 
      "bacterial cell death", 
      "mode of inhibition", 
      "DNA topoisomerase IV", 
      "DNA topoisomerases", 
      "DNA gyrase", 
      "cell death", 
      "topoisomerase IV", 
      "aminocoumarins", 
      "ATPase activity", 
      "topoisomerase inhibitors", 
      "gyrase", 
      "mode", 
      "topoisomerases", 
      "enormous success", 
      "DNA", 
      "potential", 
      "agents", 
      "enzyme", 
      "discovery", 
      "drugs", 
      "key features", 
      "inhibitors", 
      "clinical potential", 
      "variety", 
      "quinolones", 
      "breaks", 
      "inhibition", 
      "activity", 
      "ciprofloxacin", 
      "significant concern", 
      "resistance", 
      "chapter", 
      "possibility", 
      "death", 
      "levofloxacin", 
      "success", 
      "fluoroquinolones", 
      "antibiotics", 
      "terms", 
      "action", 
      "decades", 
      "features", 
      "moxifloxacin", 
      "knowledge", 
      "concern", 
      "purpose", 
      "II DNA topoisomerases", 
      "enzyme-stabilized double-stranded breaks", 
      "cleavage-complex mode", 
      "Non-quinolone Topoisomerase Inhibitors"
    ], 
    "name": "Non-quinolone Topoisomerase Inhibitors", 
    "pagination": "593-618", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1109848723"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/978-3-319-78538-7_19"
        ]
      }
    ], 
    "publisher": {
      "name": "Springer Nature", 
      "type": "Organisation"
    }, 
    "sameAs": [
      "https://doi.org/10.1007/978-3-319-78538-7_19", 
      "https://app.dimensions.ai/details/publication/pub.1109848723"
    ], 
    "sdDataset": "chapters", 
    "sdDatePublished": "2021-12-01T19:58", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20211201/entities/gbq_results/chapter/chapter_176.jsonl", 
    "type": "Chapter", 
    "url": "https://doi.org/10.1007/978-3-319-78538-7_19"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/978-3-319-78538-7_19'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/978-3-319-78538-7_19'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/978-3-319-78538-7_19'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/978-3-319-78538-7_19'


 

This table displays all metadata directly associated to this object as RDF triples.

145 TRIPLES      23 PREDICATES      77 URIs      70 LITERALS      7 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/978-3-319-78538-7_19 schema:about anzsrc-for:06
2 anzsrc-for:0601
3 schema:author N82cad8ee65de47aa90e6e2c4098c5778
4 schema:datePublished 2018-11-11
5 schema:datePublishedReg 2018-11-11
6 schema:description Fluoroquinolone antibiotics, such as ciprofloxacin, levofloxacin, and moxifloxacin, have enjoyed enormous success over the past few decades. However, resistance to these compounds is rising and causing significant concern. These drugs target the type II DNA topoisomerases, DNA gyrase, and DNA topoisomerase (topo) IV. A key feature of their success is that they cause enzyme-stabilized double-stranded breaks in DNA, which can readily lead to bacterial cell death. There are, however, many other compounds that target gyrase and topo IV both via the cleavage-complex mode of action and via other modes of inhibition, such as blocking the ATPase activity of these enzymes. The purpose of this chapter is to review our knowledge of these compounds and to discuss the possibility that one or more of these compounds will become clinically-relevant, perhaps by replacing the fluoroquinolones. Compounds covered include well-established agents, such as the aminocoumarins, which predate the quinolones in terms of their discovery, and a variety of more recently-discovered compounds whose clinical potential has yet to be fully explored.
7 schema:editor Na76296f3fc8841d28f7578abcf8cc9cc
8 schema:genre chapter
9 schema:inLanguage en
10 schema:isAccessibleForFree false
11 schema:isPartOf Ne166b696443941f3b1ddc111fc97fb42
12 schema:keywords ATPase activity
13 DNA
14 DNA gyrase
15 DNA topoisomerase IV
16 DNA topoisomerases
17 II DNA topoisomerases
18 Non-quinolone Topoisomerase Inhibitors
19 action
20 activity
21 agents
22 aminocoumarins
23 antibiotics
24 bacterial cell death
25 breaks
26 cell death
27 chapter
28 ciprofloxacin
29 cleavage-complex mode
30 clinical potential
31 compounds
32 concern
33 death
34 decades
35 discovery
36 double-strand breaks
37 drugs
38 enormous success
39 enzyme
40 enzyme-stabilized double-stranded breaks
41 features
42 fluoroquinolone antibiotics
43 fluoroquinolones
44 gyrase
45 inhibition
46 inhibitors
47 key features
48 knowledge
49 levofloxacin
50 mode
51 mode of inhibition
52 moxifloxacin
53 possibility
54 potential
55 purpose
56 quinolones
57 resistance
58 significant concern
59 success
60 terms
61 topoisomerase IV
62 topoisomerase inhibitors
63 topoisomerases
64 type II DNA topoisomerases
65 variety
66 schema:name Non-quinolone Topoisomerase Inhibitors
67 schema:pagination 593-618
68 schema:productId N6ed39f76bd174345911199f2ce7a13c9
69 Nda34cac972f645708bd1b154b65162eb
70 schema:publisher Ncea7fd0a20fa465f9ca36693bd8b0686
71 schema:sameAs https://app.dimensions.ai/details/publication/pub.1109848723
72 https://doi.org/10.1007/978-3-319-78538-7_19
73 schema:sdDatePublished 2021-12-01T19:58
74 schema:sdLicense https://scigraph.springernature.com/explorer/license/
75 schema:sdPublisher Nd4ccd1efa865457c9a06d229c9ea883d
76 schema:url https://doi.org/10.1007/978-3-319-78538-7_19
77 sgo:license sg:explorer/license/
78 sgo:sdDataset chapters
79 rdf:type schema:Chapter
80 N1887e8c54097445f97029c83c459cc99 rdf:first sg:person.0630632607.32
81 rdf:rest N5e520407a2e64de7ad7135812928e42f
82 N5e4ad2b1a94548b0b321a6181b2a65b6 schema:familyName Drlica
83 schema:givenName Karl
84 rdf:type schema:Person
85 N5e520407a2e64de7ad7135812928e42f rdf:first sg:person.015610331447.17
86 rdf:rest rdf:nil
87 N6ed39f76bd174345911199f2ce7a13c9 schema:name dimensions_id
88 schema:value pub.1109848723
89 rdf:type schema:PropertyValue
90 N82cad8ee65de47aa90e6e2c4098c5778 rdf:first sg:person.01274446176.29
91 rdf:rest Nf790c2c175ab426b9e06b42c6c7e8384
92 Na76296f3fc8841d28f7578abcf8cc9cc rdf:first Nbcde54c0806a446287431975384426e3
93 rdf:rest Nc12bffa7ccf1439b957dbc967f26a2e5
94 Naca5a4100d954151a229502814420f0b schema:familyName Shlaes
95 schema:givenName David
96 rdf:type schema:Person
97 Nbcde54c0806a446287431975384426e3 schema:familyName Fong
98 schema:givenName I. W.
99 rdf:type schema:Person
100 Nbeb8388b291d44b3899556c8b1974932 rdf:first N5e4ad2b1a94548b0b321a6181b2a65b6
101 rdf:rest rdf:nil
102 Nc12bffa7ccf1439b957dbc967f26a2e5 rdf:first Naca5a4100d954151a229502814420f0b
103 rdf:rest Nbeb8388b291d44b3899556c8b1974932
104 Ncea7fd0a20fa465f9ca36693bd8b0686 schema:name Springer Nature
105 rdf:type schema:Organisation
106 Nd4ccd1efa865457c9a06d229c9ea883d schema:name Springer Nature - SN SciGraph project
107 rdf:type schema:Organization
108 Nda34cac972f645708bd1b154b65162eb schema:name doi
109 schema:value 10.1007/978-3-319-78538-7_19
110 rdf:type schema:PropertyValue
111 Ne166b696443941f3b1ddc111fc97fb42 schema:isbn 978-3-319-78537-0
112 978-3-319-78538-7
113 schema:name Antimicrobial Resistance in the 21st Century
114 rdf:type schema:Book
115 Nf790c2c175ab426b9e06b42c6c7e8384 rdf:first sg:person.0753423055.87
116 rdf:rest N1887e8c54097445f97029c83c459cc99
117 anzsrc-for:06 schema:inDefinedTermSet anzsrc-for:
118 schema:name Biological Sciences
119 rdf:type schema:DefinedTerm
120 anzsrc-for:0601 schema:inDefinedTermSet anzsrc-for:
121 schema:name Biochemistry and Cell Biology
122 rdf:type schema:DefinedTerm
123 sg:person.01274446176.29 schema:affiliation grid-institutes:grid.14830.3e
124 schema:familyName Maxwell
125 schema:givenName Anthony
126 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01274446176.29
127 rdf:type schema:Person
128 sg:person.015610331447.17 schema:affiliation grid-institutes:grid.14830.3e
129 schema:familyName McKie
130 schema:givenName Shannon J.
131 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.015610331447.17
132 rdf:type schema:Person
133 sg:person.0630632607.32 schema:affiliation grid-institutes:grid.14830.3e
134 schema:familyName Germe
135 schema:givenName Thomas
136 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0630632607.32
137 rdf:type schema:Person
138 sg:person.0753423055.87 schema:affiliation grid-institutes:grid.14830.3e
139 schema:familyName Bush
140 schema:givenName Natassja G.
141 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0753423055.87
142 rdf:type schema:Person
143 grid-institutes:grid.14830.3e schema:alternateName Department of Biological Chemistry, John Innes Centre, Norwich Research Park, NR4 7UH, Norwich, UK
144 schema:name Department of Biological Chemistry, John Innes Centre, Norwich Research Park, NR4 7UH, Norwich, UK
145 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...